Medical Research News

RSS

Study links insomnia to higher stroke and hospitalization risks

Insomnia is associated with a 26% higher risk of stroke and 28% higher odds of hospital admission, according to new research in Sleep Medicine Reviews. The researchers say the findings support recognizing insomnia as an important marker of brain, mental and general health.

28 Sep 2026

Research makes strong case for broader use of GLP1 drugs to protect hearts

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) makes a case for extending the indication for GLP1- receptor agonists (GLP1-RAs) to millions more people, to protect their heart health.

28 Sep 2026

Continuous glucose monitors show strong survival benefits for type 2 diabetes patients

People with type 2 diabetes (T2D) on basal insulin, starting continuous glucose monitoring (CGM) had a 44% lower risk of dying from any cause after one year compared with those who did not use CGM, with the risk being 35% lower after two years, according to an analysis of patient data being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

28 Sep 2026

An AI-identified biomarker can look accurate and still fail its biggest test

The review examines how AI combines molecular, imaging, circulating, cellular, and digital data to identify potential disease biomarkers. Its authors argue that independent validation, biological testing, and evidence of better clinical decisions are needed before those candidates enter patient care.

28 Sep 2026

A survey of 371,000 adults links heart disease to eating whole fruit less often

In a survey analysis of 371,038 US adults, those reporting high blood pressure, high cholesterol, a heart attack, or coronary heart disease ate whole fruit slightly less often than those without the respective conditions. After adjustment, 100% fruit-juice consumption was less frequent among adults with high cholesterol and more frequent among those reporting a heart attack, but the cross-sectional study cannot establish cause and effect.

28 Sep 2026

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.

27 Sep 2026

Neurodivergent youth face higher risk of early-onset type 2 diabetes

People with neurodiversity, particularly autism and ADHD (attention-deficit/hyperactivity disorder), may be more likely to be diagnosed with type 2 diabetes (T2D) at younger ages, with particularly high prevalence of neurodiversity observed among individuals diagnosed with T2D before the age of 20, finds an analysis of patient data being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (September 28–October 2.

27 Sep 2026

Low-dose radiation shows lasting benefits in patients with knee osteoarthritis

Low-dose radiation therapy may do more than relieve pain from early knee osteoarthritis, with a long-term analysis suggesting it could also influence how the disease progresses.

27 Sep 2026

Why one gut microbe is attracting attention in heart failure research

Researchers found that chronic systolic heart failure caused by nonischemic cardiomyopathy was associated with reduced gut microbial diversity, depletion of Bifidobacterium, and lower microbial short-chain fatty acid production potential. Higher Bifidobacterium abundance and higher circulating indole-3-propionic acid levels were associated with milder disease and clinical improvement, although the findings do not establish causality.

27 Sep 2026

Long-term endocrine therapy adherence remains low after breast cancer surgery

Many patients with early-stage breast cancer do not consistently maintain the long-term hormone therapy prescribed after lumpectomy, a large U.S. insurance claims analysis indicates.

27 Sep 2026

$Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes$

Hypofractionated radiotherapy for prostate cancer matches conventional treatment outcomes

Men with high-risk prostate cancer have a higher likelihood of having residual disease following prostatectomy and may require radiation therapy after surgery, particularly when PSA levels begin to rise. Conventional postprostatectomy radiotherapy (COPORT) is typically delivered over 37 fractions, while hypofractionated postprostatectomy radiotherapy (HYPORT) delivers a slightly lower total radiation dose over just 25 fractions.

27 Sep 2026

Gut bacteria signature may predict type 2 diabetes risk

Changes in the composition of bacteria in the gut could provide early warning of type 2 diabetes (T2D), new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found.

27 Sep 2026

Two-molecule blood test accurately identifies infections in febrile infants

A test that compares the levels of two molecules in the blood is able to accurately distinguish between bacterial and viral infections in newborn babies with fever in a small study presented at the European Emergency Medicine Congress today (Sunday).

27 Sep 2026

Could the Mediterranean diet protect the brain through the gut?

A narrative review finds that the Mediterranean diet may support brain health through gut microbiome, immune, metabolic, and barrier-related pathways, but direct human evidence that microbiome remodeling mediates neuroprotection remains limited. The proposed mechanisms involve microbial metabolites, reduced inflammatory signaling, stronger intestinal and blood-brain barrier function, and possible effects on processes linked to Alzheimer’s and Parkinson’s diseases.

27 Sep 2026

Heated tobacco users had more hypertension, but the story is not that simple

A large Japanese real-world cohort study found that current heated tobacco product users had a higher risk of developing hypertension than never-smokers in the primary adjusted analysis. However, the association weakened in several sensitivity analyses, and the observational study could not separate the effects of current heated tobacco use from previous cigarette exposure.

27 Sep 2026

Could age help explain why psychedelic studies reach different conclusions?

A cross-sectional study of 1,088 adults found that lifetime classic psychedelic use was associated with lower current anxiety and depression symptoms among younger adults, but these associations weakened with age. Mystical experiences may partly explain the age-related pattern, although the observational design cannot establish that psychedelic use caused the mental health differences.

27 Sep 2026

Kangaroo care helps smaller babies. Now researchers are studying babies born at normal weight

Researchers examine whether extending SSC beyond the first hour can improve early weight changes, breastfeeding and other maternal and newborn outcomes in normal-birthweight infants.

27 Sep 2026

Ultra-low-dose radiation therapy eases painful bone lesions in multiple myeloma

A short course of ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients in a multi-institutional phase 2 clinical trial.

27 Sep 2026

Nasal spray offers needle-free pain relief for children with injuries

A treatment for pain, that is delivered via a nasal spray, offers an effective, needle-free option for children being seen in the emergency department for a range of injuries, according to research presented at the European Emergency Medicine Congress today (Sunday).

27 Sep 2026

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Neuraxpharm Group and Minoryx Therapeutics, today announce that the European Commission (EC) has granted marketing authorization under exceptional circumstances for NEZGLYAL® (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients, aged 2-12 years with Gadolinium (Gd)-negative brain lesions.

26 Sep 2026